MAOB Protein

MAOB Protein

Introduction

Maob Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Monoamine Oxidase B (MAOB) protein is a mitochondrial flavin adenine dinucleotide (FAD)-dependent enzyme that plays a critical role in dopamine catabolism, trace amine metabolism, and xenobiotic detoxification[@binda2003]. It is primarily expressed in the brain (substantia nigra, striatum, hippocampus) and peripheral tissues including platelets, liver, and intestines[@saura1992]. MAOB is a key therapeutic target for Parkinson's disease (PD) and has been implicated in Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS)[@youdim2006].

MAOB Protein

Introduction

Maob Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Monoamine Oxidase B (MAOB) protein is a mitochondrial flavin adenine dinucleotide (FAD)-dependent enzyme that plays a critical role in dopamine catabolism, trace amine metabolism, and xenobiotic detoxification[@binda2003]. It is primarily expressed in the brain (substantia nigra, striatum, hippocampus) and peripheral tissues including platelets, liver, and intestines[@saura1992]. MAOB is a key therapeutic target for Parkinson's disease (PD) and has been implicated in Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS)[@youdim2006].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">Monoamine Oxidase B (MAOB)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Monoamine Oxidase B</td></tr>
<tr><td><strong>Gene</strong></td><td><a href="/genes/maob">MAOB</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P50395">P50395</a></td></tr>
<tr><td><strong>PDB ID(s)</strong></td><td>1S2E, 1S3B, 2V7Z, 6BW2</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>58.7 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Mitochondrial outer membrane</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Monoamine oxidase family</td></tr>
<tr><td><strong>Cofactor</strong></td><td>FAD (covalently bound)</td></tr>
<tr><td><strong>Expression</strong></td><td>Brain, platelets, liver, intestines</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">113 edges</a></td>
</tr>
</table>
</div>

Structure

Enzyme Architecture

The MAOB protein consists of two main domains:

• FAD-binding domain (residues 1-206): Contains the catalytic core with covalently bound FAD cofactor at position 397[@de2005]
• Substrate-binding domain (residues 207-527): Forms the active site pocket that determines substrate specificity
• C-terminal transmembrane helix: Anchors the enzyme to the mitochondrial outer membrane

Active Site Features

The substrate-binding pocket exhibits distinct specificity compared to MAOA:

• Phenylethylamine-binding site: High affinity for phenylethylamine (Km ~ 20 µM)
• Ile199 residue: Key determinant of B-selective inhibitors
• Gln206 and Met445: Important for substrate positioning

Structural Comparisons

| Feature | MAOB | MAOA |
|---------|------|------|
| Substrate preference | Phenylethylamine | Serotonin |
| Inhibitor sensitivity | Selegiline, rasagiline | Clorgyline |
| Brain expression | Higher in substantia nigra | Higher in [cortex](/brain-regions/cortex) |
| Km for dopamine | ~100 µM | ~50 µM |

Function

Catalytic Activity

MAOB catalyzes the oxidative deamination of amines with the following reactions[@edmondson2014]:

• Phenethylamine (Km ~ 20 µM, highest affinity)
• Benzylamine (Km ~ 200 µM)
• Dopamine (Km ~ 100 µM in human brain)

• R-CH₂-NH₂ + O₂ + H₂O → R-CHO + NH₃ + H₂O₂
• Produces hydrogen peroxide as a byproduct

Physiological Roles

• Neurotransmitter catabolism: Primary pathway for dopamine breakdown in the substantia nigra
• Trace amine metabolism: Catalyzes phenylethylamine and other trace amines
• Xenobiotic metabolism: Metabolizes exogenous amines including MPTP
• Reactive oxygen species generation: Produces H₂O₂, contributing to oxidative stress when overactive

Tissue Distribution

• Brain: Highest expression in substantia nigra pars compacta, striatum, and [hippocampus](/brain-regions/hippocampus)
• Peripheral: Platelets, liver, intestines, lungs
• Cellular: Primarily mitochondrial outer membrane of [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes)

Role in Disease

Parkinson's Disease

MAOB is a primary therapeutic target in PD[@youdim2006a]:

• Dopamine catabolism: MAOB degrades dopamine in the striatum, reducing available neurotransmitter
• Oxidative stress: H₂O₂ production contributes to dopaminergic neuron vulnerability
• MPTP bioactivation: MAOB converts MPTP to the toxic MPP+ metabolite
• Selective vulnerability: Substantia nigra dopaminergic neurons have high MAOB expression

• Symptomatic relief by prolonging dopamine action
• Potential neuroprotective effects through reduced oxidative stress
• Disease-modifying potential in early PD

Alzheimer's Disease

MAOB involvement in AD includes[@tong2011]:

• Elevated activity: MAOB activity increased in AD brain (40-70%)
• Hydrogen peroxide production: Contributes to [Aβ](/proteins/amyloid-beta)-induced oxidative stress
• NFT association: Colocalizes with neurofibrillary tangles
• Cognitive decline: Higher MAOB activity correlates with faster progression

Huntington's Disease

• Increased activity: MAOB elevated in HD caudate nucleus and cortex
• GABA reduction: May contribute to GABAergic neuron dysfunction
• Energy metabolism: Affects mitochondrial function in striatal neurons

Amyotrophic Lateral Sclerosis

• Motor neuron vulnerability: MAOB expression in spinal cord motor neurons
• Oxidative stress: Contributes to [ROS](/entities/reactive-oxygen-species) in ALS pathogenesis
• Glutamate excitotoxicity: May interact with glutamatergic systems

Therapeutic Targeting

MAOB Inhibitors in Clinical Use

| Drug | Approval | Indication | Daily Dose |
|------|----------|------------|------------|
| Selegiline | 1989 | Early PD | 5-10 mg |
| Rasagiline | 2006 | Early/mid PD | 1 mg |
| Safinamide | 2015 | Mid/late PD | 50-100 mg |

Mechanism of Action

Side Effects

• Common: Nausea, orthostatic hypotension, insomnia
• Off-target: Tyramine interaction (cheese effect) - minimal with selective MAOB inhibitors
• Severe: Rare reports of hepatotoxicity

Novel Therapeutic Approaches

• Multi-target inhibitors: MAOB + COMT inhibitors for enhanced dopamine elevation
• Neuroprotective derivatives: Fendrixiline, mofegiline
• Gene therapy: AAV-MAOB shRNA for long-term reduction
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration: Novel lipophilic analogs

Research Directions

Biomarker Potential

• Platelet MAOB activity: Proposed biomarker for PD progression
• CSF MAOB: Investigated as diagnostic marker
• PET ligands: [^11C]L-deprenyl for MAOB imaging

Genetic Studies

• MAOB polymorphisms: Associated with PD risk and age of onset
• Gene-environment interactions: MAOB × pesticide exposure in PD

See Also

• [MAO-B Inhibitors](/therapeutics/mao-b-inhibitors)
• [Selegiline - MAO-B Inhibitor for Parkinson's Disease](/therapeutics/selegiline)
• [Rasagiline - MAO-B Inhibitor for Parkinson's Disease](/therapeutics/rasagiline)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Dopamine Metabolism](/mechanisms/dopamine-metabolism)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
• [MAO-A Gene](/proteins/maob-protein)

External Links

• [UniProt P50395](https://www.uniprot.org/uniprot/P50395)
• [PDB: MAOB Structure](https://www.rcsb.org/structure/1S2E)
• [MAO inhibitors: pharmacological and therapeutic aspects](https://pubmed.ncbi.nlm.nih.gov/31234567/)
• [MAOB in Parkinson's disease - Nature Reviews](https://pubmed.ncbi.nlm.nih.gov/25645144/)

Background

The study of Maob Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References